FGF19 and disorder of glycogen metabolism: This framework is enhanced by the incorporation of mechanism-related biomarkers that show promise for early GSD risk prediction, such as serum leptin levels, lipoprotein profiles (with particular emphasis on the apoB/apoA1 ratio), FGF19 serum concentrations, and inflammatory markers associated with MetS [70,71].